KEYMED BIO-B(02162),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

02162 KEYMED BIO-B

Market Closed 07-05 16:08:07

33.850

+2.300

+7.29%

High34.900	Low31.150	Vol598.50K
Open31.600	D1 Closing31.550	Amplitude11.89%
Mkt Cap9.47B	Tradable Cap9.47B	Total Shares279.74M
T/O19.94M	T/O Rate0.21%	Tradable Shares279.74M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"02162","market":"HK","secType":"STK","nameCN":"KEYMED BIO-B","latestPrice":33.85,"timestamp":1720166887013,"preClose":31.55,"halted":0,"volume":598500,"delay":0,"floatShares":279735566,"shares":279735566,"eps":-1.4716100348301446,"marketStatus":"Market Closed","change":2.3,"latestTime":"07-05 16:08:07","open":31.6,"high":34.9,"low":31.15,"amount":19940100,"amplitude":0.118859,"askPrice":33.85,"askSize":49000,"bidPrice":33.7,"bidSize":14000,"shortable":3,"etf":0,"ttmEps":-1.4716100348301446,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1720402200000},"marketStatusCode":7,"adr":0,"listingDate":1625673600000,"exchange":"SEHK","adjPreClose":31.55,"openAndCloseTimeList":[[1720143000000,1720152000000],[1720155600000,1720166400000]],"volumeRatio":1.310316,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02162/wiki","defaultTab":"wiki","newsList":[{"id":"2441992082","title":"Keymed Biosciences' Rhinosinusitis Drug Gets NDA Application Acceptance from NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=2441992082","media":"MT Newswires Live","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2441992082?lang=en_us&edition=fundamental","pubTime":"2024-06-07 14:32","pubTimestamp":1717741930,"startTime":"0","endTime":"0","summary":"Keymed Biosciences   said its new drug application, Stapokibart injection, for the treatment of chronic rhinosinusitis with nasal polyps, has recently been accepted by Chinas National Medical Products Administration , according to a Friday filing on the Hong Kong bourse. The shares of the pharmaceutical were over 2% down in recent trading. Price : $33.15, Change: $-0.85, Percent Change: -2.50%","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["02162","HKD","BK4023","BK1161","BK1574","BK4588","BK4585","BK1587","BK4526","BK1583"],"gpt_icon":0},{"id":"2440813054","title":"Keymed Presents Results of Phase 1 Study on Gastric/Gastroesophageal Cancer Drug; Shares Fall 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2440813054","media":"MT Newswires Live","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2440813054?lang=en_us&edition=fundamental","pubTime":"2024-06-03 10:33","pubTimestamp":1717382038,"startTime":"0","endTime":"0","summary":"Keymed Biosciences (HKG:2162) presented results of its phase 1 clinical study for its CMG901 treatment for advanced gastric/gastroesophageal junction cancer at the meeting of the American Society of C","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","BK1583","BK1574","BK1587","02162"],"gpt_icon":0},{"id":"2431655800","title":"BRIEF-Keymed Biosciences Says New Drug Application Of Stapokibart Injection Accepted By Nmpa","url":"https://stock-news.laohu8.com/highlight/detail?id=2431655800","media":"Reuters","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2431655800?lang=en_us&edition=fundamental","pubTime":"2024-04-30 09:53","pubTimestamp":1714442035,"startTime":"0","endTime":"0","summary":"April 30 (Reuters) - Keymed Biosciences Inc   :   * NEW DRUG APPLICATION OF STAPOKIBART INJECTION FOR TREATMENT OF SEASONAL ALLERGIC RHINITIS ACCEPTED BY NMPAFurther company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1587","BK1583","BK1574","02162"],"gpt_icon":0},{"id":"2431855791","title":"Keymed Biosciences Full Year 2023 Earnings: EPS Misses Expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2431855791","media":"Simply Wall St.","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2431855791?lang=en_us&edition=fundamental","pubTime":"2024-04-29 14:39","pubTimestamp":1714372795,"startTime":"0","endTime":"0","summary":"Keymed Biosciences ( HKG:2162 ) Full Year 2023 Results Key Financial Results Revenue: CN¥354.1m (up 254% from FY 2022...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2162/keymed-biosciences-shares/news/keymed-biosciences-full-year-2023-earnings-eps-misses-expect-1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4523","02162","BK1574","TTM.AU","BK1583","BK4099","BK1587","BK7104","TTM","BK1161"],"gpt_icon":0},{"id":"2424075368","title":"News Flash: 10 Analysts Think Keymed Biosciences Inc. (HKG:2162) Earnings Are Under Threat","url":"https://stock-news.laohu8.com/highlight/detail?id=2424075368","media":"Simply Wall St.","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2424075368?lang=en_us&edition=fundamental","pubTime":"2024-04-04 06:06","pubTimestamp":1712182007,"startTime":"0","endTime":"0","summary":"The analysts covering Keymed Biosciences Inc. ( HKG:2162 ) delivered a dose of negativity to shareholders today, by...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2162/keymed-biosciences-shares/news/news-flash-10-analysts-think-keymed-biosciences-inc-hkg2162","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["NWS","02162"],"gpt_icon":0},{"id":"2422644419","title":"Press Release: Keymed Biosciences Announces 2023 Annual Results and Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2422644419","media":"Dow Jones","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2422644419?lang=en_us&edition=fundamental","pubTime":"2024-03-27 01:16","pubTimestamp":1711473360,"startTime":"0","endTime":"0","summary":"-- Submitted a New Drug Application  of Stapokibart  for the. treatment of moderate-to-severe AD in adults. The NDA was accepted by the. -- Advanced a Phase III clinical study of Stapokibart for the treatment of. CRSwNP in 2023. The results of the clinical trial are positive with. co-primary endpoints both achieved. We expect to file an NDA for CRSwNP. -- Launched and advanced Phase III clinical studies respectively to evaluate. the efficacy and safety of Stapokibart in patients with seasonal allergic. rhinitis under background therapy and in adolescent subjects with. -- Entered into a global exclusive license agreement with AstraZeneca for. commercialization of CMG901 and received an upfront payment of US$63. million in 2023. As of the date of this announcement, AstraZeneca has. conducted multiple clinical studies regarding CMG901/AZD0901 for the. -- Rapidly expanded manufacturing capacity and continue to recruit talents. to meet the growing needs of commercialized sales of products, ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7095","02162","ASH","BK1574","BK7057","BK1583","ASH.AU","BK1587","SLE","BK4109","BK4077","ORR.AU","BK1161"],"gpt_icon":0},{"id":"2422641802","title":"BRIEF-Keymed Biosciences Inc Says Revenue For FY Rmb354.1 Million, Up 254%","url":"https://stock-news.laohu8.com/highlight/detail?id=2422641802","media":"Reuters","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2422641802?lang=en_us&edition=fundamental","pubTime":"2024-03-27 00:50","pubTimestamp":1711471800,"startTime":"0","endTime":"0","summary":"March 26 (Reuters) - Keymed Biosciences Inc   :   * REVENUE FOR FY RMB354.1 MILLION, UP 254%   * FY ADJUSTED LOSS RMB317.7 MILLION VERSUS LOSS RMB255.0 MILLION Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02162"],"gpt_icon":0},{"id":"2422153293","title":"Individual investors are Keymed Biosciences Inc.'s (HKG:2162) biggest owners and were hit after market cap dropped HK$1.9b","url":"https://stock-news.laohu8.com/highlight/detail?id=2422153293","media":"Simply Wall St.","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2422153293?lang=en_us&edition=fundamental","pubTime":"2024-03-25 08:29","pubTimestamp":1711326562,"startTime":"0","endTime":"0","summary":"Key Insights Significant control over Keymed Biosciences by individual investors implies that the general public has...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2162/keymed-biosciences-shares/news/individual-investors-are-keymed-biosciences-incs-hkg2162-big","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1587","BK1583","BK1161","BK1574","02162"],"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":0.003},{"period":"1month","weight":-0.0231},{"period":"3month","weight":0.134},{"period":"6month","weight":-0.1804},{"period":"1year","weight":-0.2173},{"period":"ytd","weight":-0.3106}],"compareEarnings":[{"period":"1week","weight":0.0046},{"period":"1month","weight":-0.0339},{"period":"3month","weight":0.0643},{"period":"6month","weight":0.0765},{"period":"1year","weight":-0.0396},{"period":"ytd","weight":0.0441}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Keymed Biosciences Inc is a China-based biotechnology company. The Company focuses on the independent discovery and development of innovative biological therapies that address underserved medical needs in the autoimmune and oncology therapeutic areas. The Company has mastered in-house drug discovery and development technologies, including an innovative antibody discovery platform and a proprietary novel T cell engager (nTCE) bispecific antibody platform. The Company has also established a fully integrated platform covering the key functions of biopharmaceutical development. The Company's main products include CM310, CM326 and CMG901.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.102216},{"month":2,"riseRate":0.666667,"avgChangeRate":0.052845},{"month":3,"riseRate":0,"avgChangeRate":-0.111304},{"month":4,"riseRate":1,"avgChangeRate":0.048679},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.125967},{"month":6,"riseRate":1,"avgChangeRate":0.150041},{"month":7,"riseRate":0.666667,"avgChangeRate":0.090242},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.018956},{"month":9,"riseRate":0.666667,"avgChangeRate":-0.014017},{"month":10,"riseRate":0.666667,"avgChangeRate":0.069277},{"month":11,"riseRate":0.666667,"avgChangeRate":0.090203},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.129089}],"exchange":"SEHK","name":"KEYMED BIO-B","nameEN":"KEYMED BIO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"KEYMED BIO-B(02162),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest KEYMED BIO-B(02162) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"KEYMED BIO-B,02162,KEYMED BIO-B股票,KEYMED BIO-B股票老虎,KEYMED BIO-B股票老虎国际,KEYMED BIO-B行情,KEYMED BIO-B股票行情,KEYMED BIO-B股价,KEYMED BIO-B股市,KEYMED BIO-B股票价格,KEYMED BIO-B股票交易,KEYMED BIO-B股票购买,KEYMED BIO-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"KEYMED BIO-B(02162),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest KEYMED BIO-B(02162) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}